ALPHA-BLOCKER THERAPY OF HYPERTENSION - AN UNFULFILLED PROMISE
被引:46
作者:
KHOURY, AF
论文数: 0引用数: 0
h-index: 0
机构:
UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235
KHOURY, AF
[1
]
KAPLAN, NM
论文数: 0引用数: 0
h-index: 0
机构:
UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235
KAPLAN, NM
[1
]
机构:
[1] UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235
来源:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
1991年
/
266卷
/
03期
关键词:
D O I:
10.1001/jama.266.3.394
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
For various reasons, the alpha-1-receptor blocker prazosin has been used infrequently as initial therapy for hypertension. The introduction of additional agents of this class with properties different from prazosin provides slower onset of action, which should reduce the degree of first-dose and postural hypotension and a longer duration of action, which allows for once-a-day dosage. A summary of the published data on efficacy, side effects, and special properties of this class of agents indicates that they will probably be used more extensively, particularly because of their ability to improve lipid and glucose-insulin metabolism.